In this issue:
Efficacy and safety of a third SARS-CoV- 2 vaccination in MS vaccine non-responders
NfL predicts relapse-free progression in MS
Risk factors and time to clinical symptoms of MS among patients with RIS
Treatment escalation vs immediate initiation of highly effective treatment for RRMS
Safety, tolerability, and activity of MSCs vs placebo in MS
Effect of changes in MS diagnostic criteria over 25 years on time to treatment and prognosis in patients with CIS
Effect of applying inclusion and exclusion criteria of phase III clinical trials to MS patients in routine clinical care
MSCopilot scores correlate with EDSS scores in MS
Impact of smoking cessation on MS disease progression
Clinical impact of ocrelizumab EID and associations with CD19 + B-cell repopulation
Please login below to download this issue (PDF)